CSF1R and multiple sclerosis: In fact, treatment of experimental animals with other types of CSF1R inhibitors (e.g. GW2580 or sCSF1Rinh) which do not affect microglial survival (and therefore do not provoke depletion) but halt their proliferation, promotes an anti‐inflammatory phenotype, reduces microgliosis and macrophage infiltration, improves recovery from spinal cord injury (Gerber et al., 2018), and slows the progression of amyotrophic lateral sclerosis (Martínez‐Muriana et al., 2016) or multiple sclerosis (Hagan et al., 2020), thus highlighting the potential therapeutic use of CSF1R inhibitors for human diseases.